Reduction in Donor‐Derived Cell‐Free DNA After Rejection Treatment is Associated With Improved Long Term Allograft Function
Clinical Transplantation · 2026-06 · 40 (6)
DOI: 10.1111/ctr.70603 ↗At a glance
Journal article in Clinical Transplantation, published online on 2026-06-23. Written by Lauren Schumacher and 7 co-authors. Institution: Department of Pharmacy, University of Kentucky Healthcare, Lexington, Kentucky, USA. Major MEDLINE topics: Graft Rejection, Cell-Free Nucleic Acids, Kidney Transplantation, Biomarkers. 20 references. The full text is freely available (open access, CC BY-NC 4.0). Funded by: NIH National Center for Advancing Translational Sciences.
Abstract (original language)
Donor derived cell‐free DNA (dd‐cfDNA) has become a useful biomarker for monitoring of kidney transplant rejection, however utilization after rejection is not well established. We conducted a retrospective cohort study of 64 kidney transplant recipients (KTRs) with biopsy‐proven rejection and concomitant dd‐cfDNA monitoring. The primary outcome was to examine the relationship between changes in dd‐cfDNA and allograft function after rejection. Secondary outcomes included the effect of a ≥61% dd‐cfDNA reduction on eGFR and proteinuria, and impact of persistently elevated dd‐cfDNA. The percent change in dd‐cfDNA from rejection to 6 months post‐rejection and 1‐year post‐rejection was negatively correlated with eGFR change at 1, 2, and 3 years. No correlation was seen with dd‐cfDNA values at 1 month. KTRs with at least 61% decrease in dd‐cfDNA from rejection to 1‐year post‐rejection showed improvement in eGFR at 1, 2, and 3 years. KTRs with persistently elevated dd‐cfDNA showed significantly worse change in eGFR to all time points compared to those without. Incidence of proteinuria at 1, 2, and 3 years trended lower in KTRs with ≥61% decrease in dd‐cfDNA. dd‐cfDNA was negatively correlated with eGFR, primarily at 6–12 months post‐rejection. In conclusion, persistently elevated dd‐cfDNA correlates with worse longitudinal changes in eGFR through 3 years post‐rejection.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Department of Pharmacy, University of Kentucky Healthcare, Lexington, Kentucky, USA.
- CareDx, Brisbane, California, USA.
- Division of Transplant, Department of Nephrology, University of Kentucky Healthcare, Lexington, Kentucky, USA.
- College of Pharmacy, University of Kentucky, Lexington, Kentucky, USA.
ORCID profiles: Lauren Schumacher, Olivia Philippart, Jesica Yau, Aric Schadler
Funding
- NIH National Center for Advancing Translational Sciences
Cite
APA
Schumacher, L., Philippart, O., Yau, J., Shuaib, F., Paluri, S., Castellanos, A. L., Schadler, A., & Fattah, H. (2026). Reduction in Donor‐Derived Cell‐Free DNA After Rejection Treatment is Associated With Improved Long Term Allograft Function. Clinical Transplantation, 40(6). https://doi.org/10.1111/ctr.70603
Vancouver
Schumacher L, Philippart O, Yau J, Shuaib F, Paluri S, Castellanos AL, et al. Reduction in Donor‐Derived Cell‐Free DNA After Rejection Treatment is Associated With Improved Long Term Allograft Function. Clinical Transplantation. 2026;40(6). doi:10.1111/ctr.70603
BibTeX
@article{Schumacher2026,
author = {Schumacher, Lauren and Philippart, Olivia and Yau, Jesica and Shuaib, Fawad and Paluri, Sravanthi and Castellanos, Ana Lia and Schadler, Aric and Fattah, Hasan},
title = {Reduction in Donor‐Derived Cell‐Free DNA After Rejection Treatment is Associated With Improved Long Term Allograft Function},
journal = {Clinical Transplantation},
year = {2026},
volume = {40},
number = {6},
doi = {10.1111/ctr.70603}
}
EUVIMED